The TRAIL apoptotic pathway in cancer onset, progression and therapy
RW Johnstone, AJ Frew, MJ Smyth - Nature Reviews Cancer, 2008 - nature.com
RW Johnstone, AJ Frew, MJ Smyth
Nature Reviews Cancer, 2008•nature.comTriggering of tumour cell apoptosis is the foundation of many cancer therapies. Death
receptors of the tumour necrosis factor (TNF) superfamily have been largely characterized,
as have the signals that are generated when these receptors are activated. TNF-related
apoptosis-inducing ligand (TRAIL) receptors (TRAILR1 and TRAILR2) are promising targets
for cancer therapy. Herein we review what is known about the molecular control of TRAIL-
mediated apoptosis, the role of TRAIL in carcinogenesis and the potential therapeutic utility …
receptors of the tumour necrosis factor (TNF) superfamily have been largely characterized,
as have the signals that are generated when these receptors are activated. TNF-related
apoptosis-inducing ligand (TRAIL) receptors (TRAILR1 and TRAILR2) are promising targets
for cancer therapy. Herein we review what is known about the molecular control of TRAIL-
mediated apoptosis, the role of TRAIL in carcinogenesis and the potential therapeutic utility …
Abstract
Triggering of tumour cell apoptosis is the foundation of many cancer therapies. Death receptors of the tumour necrosis factor (TNF) superfamily have been largely characterized, as have the signals that are generated when these receptors are activated. TNF-related apoptosis-inducing ligand (TRAIL) receptors (TRAILR1 and TRAILR2) are promising targets for cancer therapy. Herein we review what is known about the molecular control of TRAIL-mediated apoptosis, the role of TRAIL in carcinogenesis and the potential therapeutic utility of recombinant TRAIL and agonistic antibodies against TRAILR1 and TRAILR2.
nature.com